1.Appropriate dosage of interleukin-2 for tumor infiltrating lymphocyte cultured in self-supernatant of malignant pleura fluid
Journal of Medical Postgraduates 2003;0(03):-
Objective:To select an appropriate dosage of IL-2 for tumor infiltrating lymphocyte(TIL).Methods:Isolated by the attachment method we established,TIL was cultivated in self-supernatant of malignant pleura,with three different concentrations of IL-2,such as 6000u per ml,6000u per ml for the first administration followed by 1000u per ml,or 1000u per ml.The expansion,killing activity and phenotype changes of TIL cultured in different cultures were assessed.Results:As cultured in self-supernatant of malignant pleura fluid,the concentrations of IL-2,such as 6000u per ml or 6000u per ml for the first administration followed by 1000u per ml seemed benefit for TIL proliferation.Conclusion:6000u per ml of IL-2 for the first administration was very important.It could help TIL to activate and proliferate early.The study described here offers the possibility for TIL cultured in vitro self-supernatant of malignant pleura fluid in vitro for a short time,and then reinfuse to thorax for further expanding and controlling the malignant pleura effusion in the presence of IL-2,and thereby minimizing the risks of contamination.
2.Theories and clinical applications of biochemotherapy for malignant carcinomas
Chinese Journal of Clinical Oncology 2016;43(23):1061-1066
Chemoimmunotherapy or biochemotherapy, the combination of chemotherapy with immunotherapy, is a novel compre-hensive treatment model for malignant carcinoma. In recent years, many clinical trials have shown that biochemotherapy is associated with an improved response rate. Such biological agents include tumor vaccines, monoclonal antibodies, cytokines, and immunocompe-tent cells. In this article, we review the theories, sort the clinical applications of novel treatments, and discuss some of the problems existing in this field.
3.The use of autologous supernatant of malignant pleura effusion in culturing human tumor infiltrating lymphocytes in vitro
Journal of Medical Postgraduates 2003;0(07):-
Objective:To study the effect of autologous supernatant of malignant pleura effusion and RPMI1640 with 10% AB+ serum on the culture of tumor infiltrating lymphocytes (TIL) in vitro. Methods:Isolated by the attachment method we established, TIL was cultured in either autologous supernatant of malignant pleura fluid or RPMI1640 with 10% AB+ serum, and various types of cytokines such as (IL-2,) PHA and antibody against CD3 (OKT3) were added into both cultures. The proliferation as well as the killing activity and the phenotype changes of TIL cultured in the two kinds of cultures were compared. Results:There was no difference in the proliferation or the killing activity in vitro as well as the phenotype changes of TIL between the two kinds of cultures. Conclusion: Autologous supernatant of malignant pleura fluid could be used as TIL culture medium. The method described here made it possible for TIL to be cultured in vitro for a short time, and then reinfused back to thorax for further expanding and controlling the malignant pleura effusion in the presence of IL-2, and it alsominimized the risks of contamination.
4.ERCC1 and BRCA1 mRNAs expression levels in malignant pleural and peritoneal effusions are associated with chemosensitivity to cisplatin in vitro
Lifeng WANG ; Haitao YIN ; Xiaoping QIAN ; Wenjing HU ; Zhengyun ZOU ; Lixia YU ; Baorui LIU
Tumor 2010;(3):226-231
Objective:The aim of this study was to investigate the association of mRNA expressions of ERCC1 (excision repair cross-complementing group 1) and BRCA1 (breast cancer 1) with chemosensitivity to cisplatin in malignant pleural and peritoneal effusions.Methods:Malignant pleural and peritoneal effusions were collected from 46 patients diagnosed with stage Ⅳ malignant tumor, prospectively. The tumor cells were isolated and the sensitivity of tumor cells to cisplatin was detected by adenosine triphosphate-bioluminescence assay (ATP-TCA). Real-time quantitative PCR was used to determine the mRNA expressions of ERCC1 and BRCA1. Results:The expression level of ERCC1 mRNA was negatively correlated with sensitivity of non-small cell lung cancer (NSCLC) to cisplatin (P= 0.001, r=0.685). BRCA1 mRNA expression level had negative correlation with sensitivity to cisplatin in both NSCLC (P=0.014, r=0.541) and gastric cancer (P=0.002, r=0.625). A significant interaction was found between the effects of ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P=0.010 for all patients;P=0.027 for gastric cancer patients).Conclusion:ERCC1 and BRCA1 mRNA expression levels correlated with ex vivo chemosensitivity of tumor cells to cisplatin in malignant pleural and peritoneal effusions. Detection of both ERCC1 and BRCA1 may have a higher reliability in predicting the sensitivity of tumor cells to cisplatin than detection of single ERCC1 or BRCA1 expression.
5.Progress in chemotherapy for malignant melanoma
Practical Oncology Journal 2019;33(2):167-172
Malignant melanoma( MM) is a very malignant solid tumor that is highly invasive and has a poor prognosis. Al-though the treatment of advanced melanoma has entered the era of targeting and immunotherapy,chemotherapy is still not to be aban-doned. Chemotherapy for malignant melanoma has undergone a development process from single-drug chemotherapy,combination of two or three or even four drugs,and biochemotherapy. This article reviews the progress of chemotherapy for malignant melanoma,com-pares the main chemotherapy regimens,and looks forward into the future direction of chemotherapy.
6.Investigation of the prognostic value of immune microenvironment typing in malignant melanoma based on gene expression profile
Chinese Journal of Cancer Biotherapy 2021;28(7):709-713
[摘 要] 目的:探讨恶性黑色素瘤(malignant melanoma,MM)微环境分型对MM患者预后的评估价值。方法:对2010年7月至2017年5月在南京鼓楼医院手术切除的87例原发性MM组织进行二代测序,免疫组化法检测PD-1、PD-L1、CD3+ TIL、MSH2、MSH6、PMS2和MLH1的表达。随访患者的生存时间,分析不同免疫微环境分型对患者预后的影响及其基因表达特征。结果:根据PD-L1和TIL表达水平将87例MM患者的肿瘤微环境分为4个亚型:PD-L1+ TIL+型或双阳型(15/87,17.24%)、PD-L1+ TIL-型(15/87,17.24%)、PD-L1- TIL+型(20/87,22.99%)、PD-L1- TIL-型或双阴型(37/87,42.53%)。双阳型患者的中位无病生存期显著长于双阴型患者(P<0.05),此可能与双阴型患者存在更多CDK4、MCL1、MYC、AKT2、CCND1、FGF19等预后不良基因拷贝数扩增相关;双阳型患者PD-1表达显著高于双阴型患者(P<0.01),可能与PD-L1、TIL分别与PD-1呈共表达和共不表达有关。结论:根据PD-L1及TIL表达将MM 患者微环境分为4种亚型,能够区分MM患者预后,双阴型患者存在更多预后不良基因拷贝数扩增。
7. Helical tomotherapy using simultaneously integrated boost and simultaneous integrated protection technique for unresectable biliary tract cancer
Weiwei KONG ; Ju YANG ; Jing YAN ; Zhengyun ZOU ; Jie SHEN ; Juan LIU ; Shuangshuang LI ; Xia ZHOU ; Yudong QIU ; Baorui LIU
Chinese Journal of Surgery 2019;57(4):293-298
Objective:
To evaluate the safety and efficacy of helical tomotherapy using simultaneously integrated boost and simultaneous integrated protection technique in the treatment of unresectable biliary tract cancers.
Methods:
The data of 23 patients with unresectable biliary tract cancer who received tomotherapy-based hypofractionated radiotherapy at Comprehensive Cancer Centre of Drum Tower Hospital,the Affiliated Drum Tower Clinical College of Nanjing Medical University between February 2015 and October 2017 were analyzed. There were 10 males and 13 females, aged from 40 to 85 years(median:58 years). Pathological type included intrahepatic cholangiocarcinomas(